- Report
- November 2021
United Kingdom
From €3185EUR$3,500USD£2,731GBP
- Report
- November 2021
Spain
From €3185EUR$3,500USD£2,731GBP
- Report
- November 2021
Japan
From €3185EUR$3,500USD£2,731GBP
- Report
- November 2021
Italy
From €3185EUR$3,500USD£2,731GBP
- Report
- November 2021
Germany
From €3185EUR$3,500USD£2,731GBP
- Report
- November 2021
France
From €3185EUR$3,500USD£2,731GBP
- Report
- November 2021
Japan, United States, ... Japan, United States, Europe, Global
From €22297EUR$24,500USD£19,115GBP
- Report
- November 2021
Canada, Mexico, North America Canada, Mexico, North America
From €8646EUR$9,500USD£7,412GBP
- Report
- November 2021
Middle East
From €8646EUR$9,500USD£7,412GBP
- Report
- November 2021
Latin America
From €13196EUR$14,500USD£11,313GBP
- Report
- November 2021
Europe
From €22297EUR$24,500USD£19,115GBP
- Report
- November 2021
Asia Pacific
From €13196EUR$14,500USD£11,313GBP
- Report
- November 2021
Global
From €31398EUR$34,500USD£26,918GBP

The Von Willebrand Factor (VWF) is a glycoprotein found in the blood that plays an important role in hemostasis. It is a key component of the coagulation cascade, and is essential for the formation of a stable platelet plug during the clotting process. VWF is also involved in the adhesion of platelets to the site of injury, and is important for the maintenance of normal platelet function.
VWF is used in the treatment of several hematological disorders, including von Willebrand disease, thrombocytopenia, and hemophilia. VWF is available in both recombinant and plasma-derived forms, and is used in the form of concentrates, injections, and topical creams.
The VWF market is a rapidly growing segment of the hematological drugs market, driven by the increasing prevalence of hematological disorders and the growing demand for effective treatments. The market is expected to continue to grow in the coming years, driven by the development of new treatments and the increasing availability of VWF products.
Some of the major companies in the VWF market include CSL Behring, Grifols, Octapharma, Kedrion, and Shire. Show Less Read more